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A B S T R A C T
The ESC and the EACTS have collaborated to issue the 3rd updated Guidelines re-
garding myocardial revascularization. The present document highlights the key mes-
sages and changes of the recent Guidelines regarding: the broad use of DES, the im-
pact of functional assessment of intermediate-grade stenosis especially in MVD, the 
importance of intracoronary imaging and finally the trend towards extending DAPT.
I N T R O D U C T I O N 
Fifty years after the 1st CABG, the ESC and the EACTS have collaborated to issue 
the 3rd updated guidelines regarding myocardial revascularization. In these guidelines, 
ESC and EACTS provide recommendations for revascularization of SCAD, NSTEMI, 
STEMI, and revascularization in patients with different risk factors. The authors 
underline the importance of the interaction between cardiologists, cardiac surgeons, 
and referring physicians for choosing the best possible revascularization approach. 
Herein we represent the key messages of the recently published 2018 guidelines. Sum-
maries of the key changes in comparison with the previous Guidelines are provided 
in Figures 1 and 2.
A C C e S S :
The radial access should be the preferred approach for coronary angiography and 
PCI, unless there are overriding procedural considerations, (class I recommendation). 
However, the benefit of radial over femoral access depends upon the operator’s ex-
pertise in the radial technique1.
S T e N T S :
Implantation of new-generation DES is the standard treatment strategy irrespective 
of clinical presentation, lesion type, anticipated duration of DAPT, or concomitant 
anticoagulant therapy (class I recommendation)2. Bare metal stents should be used 
exceptionally.
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AbbreviAtion List: 
ACS: Acute coronary syndrome
CABG: Coronary artery bypass grafting 
procedure 
CAD: Coronary artery disease
CTO: Chronic total occlusion
DAPT: Dual antiplatelet therapy
DES: Drug-eluting stents
DM: Diabetes mellitus
EACTS: European Association for 
Cardio-Thoracic Surgery
ESC: European Society of Cardiology
HF: Heart failure 
FFR: Fractional Flow Reserve
SCAD: Stable coronary artery disease 
IABP: Intra-aortic balloon pump 
IVUS: Intravascular Ultrasound
LM: Left main
LVEF: Left ventricular ejection fraction





NOAC: Non-Vitamin K antagonist oral 
anticoagulants
OAC: Oral anticoagulation
OCT: Optical coherence tomography
PCI: Percutaneous Coronary Intervention
RCT: Randomized controlled trial
SB: Side branch 
STEMI: ST-segment elevation myocardial 
infarction 
NSTEMI: Non-ST-segment elevation 
acute coronary syndrome 
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FIgURe 1. New recommendations of the recent guidelines.
S T A B l e  C O R O N A R y  A R T e R y  D I S e A S e :
Optimal medical therapy is of important value in patients 
with SCAD (ORBITA Trial). However, in such patients 
revascularization indications are the persistence of symptoms 
despite guideline-recommended medical treatment and/or 
the improvement of prognosis. Revascularization reduces 
the use of antianginal drugs, improves exercise capacity and 
quality of life compared with conservative strategy alone dur-
ing short- and long-term follow-up. Therefore, the ability to 
achieve complete revascularization is a key issue when choos-
ing the appropriate treatment strategy (Class IIa indication). 
SCAD patients with complex CAD, anatomy as reflected by 
a high (>33) SyNTAX score (http://www.syntaxscore.com), 
such as patients with left main or 3-vessel disease (3VD), 
should be generally discussed by the Heart Team and not be 
treated ad-hoc3.
I S O l A T e D  p R O x I m A l  l e F T  A N T e R I O R 
D e S C e N D I N g  C A D :
Both CABG and PCI share similar outcomes in terms of 
death, myocardial infarction, and stroke (class I recommenda-
tion). However, we should point out the higher risk of repeat 
revascularization in PCI group4.
m U l T I v e S S e l  D I S e A S e :
In SCAD patients calculation of Syntax score should be 
consider (class I recommendation)3. PCI should not be used 
in case of 3VD with intermediate or high SyNTAX score 
(>22) especially when DM is combined (class III indication). 
l e F T  m A I N  C O R O N A R y  D I S e A S e :
CABG is “always an option,” with a class I indication in 
all patients regardless of SyNTAX Score. However, patients 
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with left main disease and low SyNTAX score (<23), PCI 
is a class I recommendation. For those with an intermediate 
(23-33) and high (>33) SyNTAX score, PCI is a class IIa and 
III recommendation, respectively. 
B I F U R C A T I O N  l e S I O N S :
MB standalone stenting with provisional stenting of the SB 
should be the preferred approach (class I indication, upgrade) 
for most bifurcation lesions. Exceptions to this rule (where 
upfront SB stenting may be preferable) include the presence 
of a large SB (≥2.75mm) with a long ostial SB lesion (>5mm) 
or anticipated difficulty in accessing an important SB after 
MB stenting, and true distal LM bifurcations. When a 2-stent 
strategy is necessary, which technique should be preferred is 
debated. In LM true bifurcation lesions, double-kissing crush 
has the most favorable outcome data. 
C A B g :
The superiority of CABG over medical therapy was es-
tablished in a meta-analysis of seven RCTs more than two 
decades ago, demonstrating a survival benefit of CABG in 
patients with SCAD and LM or 3VD, particularly when the 
proximal Left Anterior Descending artery was involved5. 
Multiple arterial grafting should be considered using the 
radial artery for high-grade stenosis and/or BIMA grafting 
for patients who do not have an increased risk of sternal 
wound infection. Off-pump surgery with no-touch aorta for 
high-risk patients should also be considered. In patients with 
ongoing ischemia or hemodynamic instability with an indica-
tion for CABG, emergency surgery should be performed and 
not postponed as a consequence of antiplatelet treatment 
exposure. 
N O N - S T- S e g m e N T  e l e vA T I O N  A C S :
The principles of SCAD should be applied in all stabilized 
patients with NSTE-ACS. In patients with MVD NSTE-ACS 
complete revascularization of significant lesions should be 
attempted. The prognosis of patients with incomplete revas-
cularization is known to be worse. In addition, complete 
one-stage revascularization strategy is associated with better 
clinical outcome compared to multistage PCI.
S T- S e g m e N T  e l e vA T I O N  m y O C A R D I A l 
I N FA R C T I O N :
Routine revascularization of non-infraction related lesions 
should be considered in STEMI patients with MVD before 
hospital discharge (class IIa recommendation).
C A R D I O g e N I C  S h O C K :
Acute myocardial ischemia in the setting of ASC is the 
antecedent event for the majority of patients with cardiogenic 
shock undergoing percutaneous revascularization. In such 
patients the routine revascularization of non-culprit lesions 
is not recommended (Class III indication). In patients with 
Cardiogenic Shock routine use of IABP is not recommended 
(IABP SHOCK Trial)6. 
FIgURe 2. Upgrading or undergrading recommendations based on the recent guidelines.
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Indeed, studies (such as DEFER or DEFINE-FLAIR Trials) 
have shown that PCI can be safely deferred if FFR is >0.759. 
Ostial lesions and FFR:
Special care must be taken to avoid a wedge position of 
the guiding catheter and using intravenous rather than intra-
coronary adenosine. 
m v D  A N D  F F R :
FFR may be useful for the selection of lesions requiring 
revascularization in patients with MV CAD and should be 
the preferred management strategy in such patients, (class 
IIa recommendation)10. However, in NSTEMI patients the 
prognostic role of FFR needs further clarification. 
l m  A N D  F F R :
The presence of intermediate grade LM stem disease is 
not infrequent and angiographic evaluation may be challeng-
ing. Assessment using FFR is more challenging vs. non-LMS 
stenosis due to the requirement for disengagement of the guid-
ing catheter and an inability to administer ic adenosine. It is 
important to consider the potential influence of any untreated 
downstream disease in the Left Anterior Descending or left 
circumflex arteries, which may be associated with an increased 
risk of a false negative FFR.
A O R T I C  S T e N O S I S  A N D  F F R :
In case of concomitant severe AS and intermediate CAD 
there are no adequate RCT data supporting the use of FFR 
for the guidance of revascularization decisions.
F F R  A N D  I C  v S .  I v  A D e N O S I N e 
A D m I N I S T R A T I O N :
Iv administration provides a stable and maximal hyperemia 
and thus should be recommended.
I N T R AvA S C U l A R  I m A g I N g :
IVUS is an ultrasound-based modality with an axial 
resolution of about 150 µm, allowing a real-time tomo-
graphic assessment of: vessel size, lumen area, and plaque 
composition and volume11. In comparison the OCT, which 
is a light-based modality, has more limited spatial resolution 
but better penetration depth allowing a better vessel sizing. 
OCT for stent optimization received an upgrade in to Class 
IIa recommendation. Both imaging modalities can be used 
for control of optimum stent apposition. Potential clinical use 
of intravascular imaging for diagnostic assessment in patients 
being considered for myocardial revascularization is also the 
evaluation of stenosis severity in lesions with intermediate-
grade stenosis. However, based on a recently published 
prospective registry showing moderate correlation between 
minimal lumen area and FFR values we suggest the use of 
FFR as a modality of choice9.
h e A R T  FA I l U R e :
In patients with regional wall motion abnormalities and HF 
can be caused by stunned or hibernating myocardium and may 
be reversed by revascularization. Assessment of myocardial 
viability may be done in order to select patients that are more 
likely to benefit from myocardial revascularization and can be 
achieved with several imaging modalities. According to STICH 
trial 10 years results coronary revascularization is superior 
in improving survival in patients with HF (LVEF ≤35%) of 
ischemic origin, compared with medical therapy alone (Class 
I indication)7. However, the optimal revascularization strat-
egy is not well defined. The choice between CABG and PCI 
should be made by the Heart Team after careful evaluation 
of the patient’s clinical status and coronary anatomy, expected 
completeness of revascularization, myocardial viability, co-
existing valvular disease, and comorbidities. As a rule, PCI 
should be considered in older patients without DM in whom 
complete revascularization can be achieved, whereas CABG 
is preferred in younger patients with more extensive CAD, 
or those with DM. In patients with DM and LV moderate or 
severe dysfunction, CABG is associated with better long-term 
survival and reduced incidence of MACCE. 
R e vA S C U l A R I z A T I O N  A N D  vA lv U l A R  h e A R T 
D I S e A S e :
Mitral Valve disease:
Patients with concomitant severe primary MR
 
should un-
dergo mitral valve repair at the time of CABG in keeping
 
with 
guidance for the surgical repair of primary MR. Controversy 
exists about the treatment of moderate secondary or ischemic 
MR in patients undergoing CABG. However, mitral valve 
surgery is indicated in patients with severe secondary MR 
undergoing CABG and LVEF >30% (Class I indication). Sur-
gery should be considered in symptomatic patients with severe 
secondary MR and LVEF <30%, but with evidence of myo-
cardial viability and an option for surgical revascularization.
Aortic Valve disease:
In the current era of rapid developments in transcatheter 
valve implantation technologies, a decision regarding replace-
ment of the
 
aortic valve for moderate stenosis/regurgitation 
should be carefully considered on a case-by-case basis in col-
laboration with the Heart Team8. 
p R e S S U R e - D e R I v e D  F R A C T I O N A l  F l O w 
R e S e R v e :
According to new guidelines the current standard of care 
for the functional assessment of lesion severity in patients 
with intermediate-grade stenosis (40–90% stenosis) without 
evidence of ischemia in non-invasive testing is FFR, (class I 
indication). Moreover compared to intravascular imaging, 
hemodynamic assessment with FFR should be preferred 
for this indication, using as a cut of point the value of ≤0.80. 
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LM and IVUS:
Assessment of intermediate-grade LM disease using IVUS 
is supported by data coming from observational studies using 
as a cut of point of Minimal lumen area (MLA) <6mm2, (class 
IIa recommendation).
A N T I p l A T e l e T  T R e A T m e N T :
The type and the duration of DAPT should be individu-
alized according to ischemic and bleeding risks, and must 
appropriately adapted during follow-up (Figure 3). Based on 
this judgment, treatment durations for DAPT after DES that 
are as short as 1 month or even as long as lifelong may be 
reasonable. However, is generally recommended after PCI in 
SCAD a 6 months DAPT, while in ACS a 12 months DAPT9.
A N T I C O A g U l A T I O N  T R e A T m e N T :
Compared with OAC therapy alone, the addition of DAPT 
to OAC therapy results in a 2- to 3-fold increase in bleeding 
complications. Every effort should be undertaken to avoid 
bleeding10. Based on the favorable bleeding risk in the large 
phase 3 studies, NOACs should be preferred over Vitamin 
K antagonists (Class IIa indication)9. In general, strategies 
to avoid bleeding complications in OAC patients should be:
 - Assessment of ischemic and bleeding risks using validated 
risk predictors (e.g. CHA2DS2-VASc and HAS-BLED) 
with a focus on modifiable risk factors.
 - Triple therapy duration must be kept as short as possible, 
dual therapy after PCI (OAC and clopidogrel) to be con-
sidered instead of triple therapy. 
 - Clopidogrel should be the P2y12 inhibitor of choice.
 - Low-dose (≤100 mg/d) of aspirin should be used.
 - NOACs should be preferred in patients with non-valvular 
atrial fibrillation requiring OAC and antiplatelet treat-
ment, (class IIa recommendation). 
Patients unfavorable for a combination of OAC and anti-
platelet therapy are those with: advanced age, end stage renal 
disease, anemia, poor mental status, short life expectancy, on-
going malignancy, prior major bleeding or hemorrhagic stroke 
and chronic alcohol abuse. Whereas, patients with high risk 
for ischemic events are those with: diffuse MVD, especially in 
FIgURe 3. Graphic summarizing the different options of DAPT with its durations based on the different characteristics of the pa-
tients (SCAD vs. ACS).
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diabetic patients, BLs, CTOs, long stented length (>60mm), 
multiple (>3) stent implantation, prior stent thrombosis, or 
renal failure. 
C O N C l U S I v e  R e m A R K S 
With this paper we briefly highlight the key messages and 
changes of the recent Guidelines on Myocardial Revasculariza-
tion regarding: the broad use of DES, the impact of functional 
assessment of intermediate-grade stenosis especially in MVD, 
the importance of intracoronary imaging and finally the trend 
towards extending DAPT. However, there are many gaps (Ta-
ble 1) that should be addressed in a future version.
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TABLE 1. Gaps in the new guideline recommendations
NSTE-ACS: There are no dedicated prospective studies on 
the revascularization strategy with MVD. 
STEMI: Patients undergoing primary PCI benefit from full 
revascularization
 
however the optimal timing of treatment of 
the non-culprit lesion is not known. 
Valvular Heart Disease: In patients with concomitant valvular 
and coronary disease, the possibility of future transcatheter 
therapy for the aortic and mitral valves has made a significant 
impact on decision-making for patients with predominantly 
coronary disease with moderate valve lesions. 
Atrial fibrillation: The duration of anticoagulation and their 
combination with antiplatelet therapy in patients with new-onset 
AF after PCI or CABG has not been studied sufficiently studied. 
CKD: Patients with CKD have been excluded from randomized 
trials on myocardial revascularization. A randomized trial on 
optimal long-term revascularization strategies in patients with 
moderate-to-severe CRD is currently ongoing.
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